克罗恩病诱导试验中安慰剂的内镜下应答率:5项随机对照试验汇总分析
本研究基于5项随机双盲安慰剂对照诱导试验的188例安慰剂患者个体数据,集中判读内镜评估克罗恩病活动度。汇总安慰剂内镜下应答率为16.2%(95%CI 10.5%-22.0%),缓解率为5.2%(95%CI 1.7%-8.8%)。既往使用TNF拮抗剂(OR 0.31)和基线CRP升高(每10 mg/L OR 0.93)与更低安慰剂应答率独立相关。
要点
- 克罗恩病诱导试验中安慰剂内镜下应答率16.2%,缓解率5.2%。
- 既往TNF拮抗剂暴露者安慰剂应答率更低(OR 0.31)。
- 基线CRP每升高10 mg/L,安慰剂应答率更低(OR 0.93)。
核心结论
- 集中判读内镜评估的克罗恩病诱导试验中,安慰剂应答率和缓解率均较低。
- 这些估计值可用于以SES-CD为终点的随机安慰剂对照试验的样本量计算。
- 这些估计值也为解读非安慰剂对照、前瞻性、随机、非盲试验提供基准。
研究设计与样本
- 汇总5项随机双盲安慰剂对照诱导试验的个体患者数据,纳入188例安慰剂患者。
- 试验药物包括eldelumab、filgotinib、risankizumab和ustekinumab,均采用集中判读内镜评估和验证评分指数。
- 主要结局为基于内镜评估的安慰剂应答率(SES-CD降低>50%),次要结局为内镜下缓解率。
- 采用逆方差加权平均法计算总率并给出95%CI。
- 利用filgotinib和ustekinumab试验的患者个体数据进行多变量meta回归分析,确定安慰剂应答的决定因素。
主要发现
- 安慰剂组汇总内镜下应答率为16.2%(95%CI 10.5%-22.0%)。
- 安慰剂组内镜下缓解率为5.2%(95%CI 1.7%-8.8%)。
关键数值与推荐
- 内镜下应答定义为SES-CD降低>50%。
- 内镜下缓解基于内镜评分判定。
临床怎么用
- 这些安慰剂应答率和缓解率估计值可用于以SES-CD为终点的随机安慰剂对照试验的样本量计算。
- 这些估计值可作为解读非安慰剂对照、前瞻性、随机、非盲试验结果的基准。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Endoscopy is used to measure activity of Crohn's disease (CD) and determine eligibility and outcomes of participants in randomized controlled trials of therapeutic agents. We aimed to estimate the rate of response to placebo in trials, based on endoscopic evaluation of CD activity, and identify factors that affect this response. METHODS: We collected patient-level data from randomized, double-blind, placebo-controlled trials of therapeutic agents for CD that included centrally-read endoscopic assessments with validated scoring indices. We analyzed data from induction trials of eldelumab, filgotinib, risankizumab, and ustekinumab (from 188 patients given placebo). The primary outcome was the rate of response to placebo, based on endoscopic assessment of CD activity (>50% reduction in the simple endoscopic score for CD). Rate of remission, based on endoscopic score, was a secondary outcome. Overall rates of response to placebo were calculated using the inverse variance-weighted average method and presented with 95% CIs. We performed a multi-variable meta-regression analysis to identify determinants of response to placebo, assessed endoscopically, using patient-level data from the filgotinib and ustekinumab trials. RESULTS: The pooled rate of response among patients given placebo was 16.2% (95% CI, 10.5%-22.0%) and the rate of remission in this group was 5.2% (95% CI, 1.7%-8.8%). Prior exposure to tumor necrosis factor antagonists (odds ratio, 0.31; 95% CI, 0.10-0.93; P = .036) and increased concentration of C-reactive protein at baseline (odds ratio, 0.93; 95% CI, 0.87-0.98; P = .014 per 10 mg/L increase) were independently associated with lower rates of response to placebo. CONCLUSIONS: Rates of response and remission to placebo, determined by centrally-read endoscopy, in induction trials of therapies for CD are low. These estimates are important for sample size calculations for randomized placebo-controlled trials that use the Simple Endoscopic Score for CD as an endpoint. They also provide a benchmark to interpret findings from non-placebo controlled, prospective, randomized, unblinded trials.
引用
- Duijvestein M, Jeyarajah J, Guizzetti L, et al. Response to Placebo, Measured by Endoscopic Evaluation of Crohn's Disease Activity, in a Pooled Analysis of Data From 5 Randomized Controlled Induction Trials. Clin Gastroenterol Hepatol. 2019. PMID: 31442599. doi:10.1016/j.cgh.2019.08.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。